Bernd Kieseier
Overview
Explore the profile of Bernd Kieseier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mallucci G, Zimmer A, Sfikas N, Cerda-Fuertes N, Wunderlin S, Athanasopoulou I, et al.
Mult Scler
. 2024 Dec;
:13524585241305966.
PMID: 39704409
Background: Neurostatus-Expanded Disability Status Scale (EDSS) is the standard measure used to assess impairment and disability in multiple sclerosis (MS) trials but requires trained expert neurologists. Objectives: This study aims...
2.
Ziemssen T, Arnold D, Alvarez E, Cross A, Willi R, Li B, et al.
Front Immunol
. 2022 Apr;
13:852563.
PMID: 35432382
Objective: This study aims to confirm the prognostic value of baseline serum neurofilament light chain (sNfL) for on-study disease activity and worsening in patients with relapsing MS (RMS). Background: Previous...
3.
Gartner J, Hauser S, Bar-Or A, Montalban X, Cohen J, Cross A, et al.
Mult Scler
. 2022 Mar;
28(10):1562-1575.
PMID: 35266417
Background: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving...
4.
Calabresi P, Kappos L, Giovannoni G, Plavina T, Koulinska I, Edwards M, et al.
Ann Clin Transl Neurol
. 2021 Oct;
8(11):2166-2173.
PMID: 34704393
Objective: To assess the independent contributions of clinical measures (relapses, Expanded Disability Status Scale [EDSS] scores, and neuroperformance measures) and nonclinical measures (new brain magnetic resonance imaging [MRI] activity and...
5.
Hersh C, Kieseier B, de Moor C, Miller D, Campagnolo D, Williams J, et al.
Mult Scler J Exp Transl Clin
. 2021 May;
7(2):20552173211004634.
PMID: 33948221
Background: Optimizing multiple sclerosis treatment warrants understanding of changes in physical, mental, and social health. Objective: To assess the impact of natalizumab on Quality of Life in Neurological Disorders (Neuro-QoL)...
6.
Hassler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, et al.
PLoS Med
. 2020 Oct;
17(10):e1003348.
PMID: 33125391
Background: Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence...
7.
Herrmann A, Wullner V, Moos S, Graf J, Chen J, Kieseier B, et al.
Free Radic Biol Med
. 2019 Jul;
141:338-347.
PMID: 31279969
Dimethyl fumarate (DMF) is widely used to treat the human autoimmune diseases multiple sclerosis (MS) and psoriasis. DMF causes short-term oxidative stress and activates the antioxidant response via the transcription...
8.
Jensen P, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, et al.
J Neuroimmunol
. 2018 Nov;
326:19-27.
PMID: 30447419
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested...
9.
Link J, Ramanujam R, Auer M, Ryner M, Hassler S, Bachelet D, et al.
PLoS One
. 2017 Feb;
12(2):e0170395.
PMID: 28170401
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the...
10.
Bachelet D, Hassler S, Mbogning C, Link J, Ryner M, Ramanujam R, et al.
PLoS One
. 2016 Nov;
11(11):e0162752.
PMID: 27806057
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical...